▲ Peaking
Business
🔮 fades
MapLight shares sink on mixed ph. 2 schizophrenia readout
MapLight Therapeutics shares have declined following the release of mixed Phase 2 topline results from the ZEPHYR trial for its schizophrenia drug candidate.